Podcast: Facilitating Patient Monitoring in CAR-T Development
Executive Summary
The US FDA recently initiated class safety labeling changes after evaluating the safety of CAR-T cancer treatment therapies. What does this mean for developers in the CAR-T landscape? Listen to your free podcast to find out.
Listen in on the conversation as experts from Cerba Research discuss facilitating patient safety measures in CAR-T therapies by accurately identifying the integration of viral vectors, utilizing flow cytometry, and more.
Listen now as experts discuss answers to:
-
What patient monitoring is required by the FDA?
-
What molecular technology does Cerba Research use and how does it meet FDA requirements?
-
What is the importance of cytometry assays in monitoring CAR-T cells?
-
What are the opportunities for combining flow cytometry with genomic solutions?
-
What key innovations are poised to improve patient monitoring in clinical trials?